Late-breaking Phase 3 REDUCE-2 data show clinically meaningful and durable serum urate lowering with pozdeutinurad
· prnewswire.com · popularity 20/100 · 0 similar stories today
Read the original at prnewswire.com →
Summary
Detailed efficacy and safety results from the pivotal phase 3 study demonstrate statistically significant serum urate reductions through 12 months Pozdeutinurad is an investigational, once-daily, highly selective URAT1 inhibitor STOCKHOLM, Oct. 29, 2026 /PRNewswire/ -- Sobi® (STO: SOBI)...
Found in: PR Newswire. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 5.